Piper Sandler Reaffirms Their Buy Rating on Amgen (AMGN)
In a report released today, David Amsellem from Piper Sandler reiterated a Buy rating on Amgen, with a price target of $432.00.
End of Quarter Sale - 50% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
According to TipRanks, Amsellem is a 4-star analyst with an average return of 6.5% and a 50.90% success rate. Amsellem covers the Healthcare sector, focusing on stocks such as Amgen, Biogen, and AbbVie.
In addition to Piper Sandler, Amgen also received a Buy from Scotiabank’s Louise Chen in a report issued on March 24. However, today, Wells Fargo assigned a Hold rating to Amgen (NASDAQ: AMGN).
Based on Amgen’s latest earnings release for the quarter ending December 31, the company reported a quarterly revenue of $9.9 billion and a net profit of $1.33 billion. In comparison, last year the company earned a revenue of $9.09 billion and had a net profit of $627 million
Read More on AMGN:
Disclaimer & DisclosureReport an Issue
- FDA identifies cases of serious liver injury in patients taking Tavneos
- Amgen announces data on Repatha from Phase 3 Vesalius-CV trial
- Amgen’s Rocatinlimab Trial Completion Signals Next Phase for Atopic Dermatitis Strategy
- Amgen Expands Oncology Pipeline With New Phase 1 AMG 436 Study in MSI-H/dMMR Tumors
- Vertex Pharmaceuticals price target raised to $550 from $515 at Wells Fargo
